Many of the FDA approved therapies for MS target CD4+ T cell signaling pathways, conversion of CD4+ T cells to T helper cells (Th1 and Th2), and transition of Th1- cells to Th17-T cells [4,10,11]. The gene discussed is CD4; the disease is myeloid sarcoma.